(d)

On April 13, 2017, the board of directors (the “Board”) of Juno Therapeutics, Inc. (“Juno”), upon recommendation from the nominating and governance committee of the Board, appointed Rupert Vessey, BM BCh, DPhil to the Board to fill an existing Class III director vacancy. The Board also appointed Dr. Vessey to the scientific committee of the Board.

Dr. Vessey has been named by Celgene Corporation (“Celgene”) as its new director designee to Celgene’s director designation rights under the Voting and Standstill Agreement (the “Voting Agreement”), dated June 29, 2015, among Juno, Celgene, and a subsidiary of Celgene. Dr. Vessey replaces Thomas O. Daniel, M.D. as Celgene’s designee on the Board. Dr. Daniel, who retired from Celgene on June 30, 2016, continues to serve on the Board as an independent director.

Neither Dr. Vessey nor any of his immediate family members has any direct or indirect material interest in any transactions required to be disclosed to Item 404(a) of Regulation S-K, other than the Voting Agreement, collaboration agreement, CD19 license agreement, share purchase agreement, and registration rights agreement by and among Juno, Celgene, and a subsidiary of Celgene. These agreements are described under the caption “Licenses and Third-Party Research Collaborations” in Part I—Item 1—”Business” of Juno’s Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 1, 2017.

In connection with his appointment, Juno and Dr. Vessey have entered into Juno’s standard director indemnification agreement, the form of which was filed with the Securities and Exchange Commission on November 17, 2014 as Exhibit 10.18 to Juno’s registration statement on Form S-1. Dr. Vessey has waived all compensation under Juno’s Non-Employee Director Compensation Policy.

About Juno Therapeutics, Inc. (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171) and JCAR020: MUC-16/IL-12. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.

Juno Therapeutics, Inc. (NASDAQ:JUNO) Recent Trading Information

Juno Therapeutics, Inc. (NASDAQ:JUNO) closed its last trading session up +0.78 at 24.61 with 712,324 shares trading hands.